Acumen Pharmaceuticals (ABOS) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Outlook Therapeutics (OTLK) over the past year, gaining 11.7% versus a loss of 55.2%. Over five years, ABOS leads with a -84.5% price change compared with -98.7% for OTLK. Acumen Pharmaceuticals is the larger company by market cap ($151.9 million vs $137.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | OTLK |
|---|---|---|
| Share price | $2.10 | $0.564 |
| Market cap | $151.87M | $137.30M |
| 1-day change | 0.00% | -4.41% |
| YTD return | -0.47% | -64.30% |
| 1-year return | +11.70% | -55.24% |
| 5-year return | -84.50% | -98.66% |
| EPS (TTM) | $-1.64 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $2.54 |
| 52-week low | $1.50 | $0.161 |
| Distance from 52-week high | -41.67% | -77.78% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +261.90% | +791.84% |
| Average volume | 439.10K | 13.33M |
| Shares outstanding | 72.32M | 243.45M |
| Employees | 60 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed OTLK by 66.9 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
ABOS vs OTLK FAQ
Which is bigger, Acumen Pharmaceuticals or Outlook Therapeutics?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $151.87M compared with $137.30M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, ABOS or OTLK?
ABOS returned +11.70% over the past 12 months, compared with -55.24% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Outlook Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.